

# Qing Liu

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/52254/publications.pdf>

Version: 2024-02-01

66  
papers

2,820  
citations

257450

24  
h-index

189892

50  
g-index

66  
all docs

66  
docs citations

66  
times ranked

3658  
citing authors

#	ARTICLE	IF	CITATIONS
1	Inherited rare and common variants in PTCH1 and PTCH2 contributing to the predisposition to reproductive cancers. <i>Gene</i> , 2022, 814, 146157.	2.2	4
2	Deintensified Chemoradiotherapy for Pretreatment Epstein-Barr Virus DNA-Selected Low-Risk Locoregionally Advanced Nasopharyngeal Carcinoma: A Phase II Randomized Noninferiority Trial. <i>Journal of Clinical Oncology</i> , 2022, 40, 1163-1173.	1.6	25
3	A diagnostic and predictive lncRNA lnc-MPEG1-1 promotes the proliferation and metastasis of papillary thyroid cancer cells by occupying miR-766-5p. <i>Molecular Therapy - Nucleic Acids</i> , 2022, 28, 408-422.	5.1	8
4	Elective upper-neck versus whole-neck irradiation of the uninvolved neck in patients with nasopharyngeal carcinoma: an open-label, non-inferiority, multicentre, randomised phase 3 trial. <i>Lancet Oncology</i> , The, 2022, 23, 479-490.	10.7	43
5	Association between solid fuel use and seropositivity against Epstein-Barr virus in a high-risk area for nasopharyngeal carcinoma. <i>Environmental Pollution</i> , 2022, 304, 119184.	7.5	2
6	A polygenic risk score for nasopharyngeal carcinoma shows potential for risk stratification and personalized screening. <i>Nature Communications</i> , 2022, 13, 1966.	12.8	19
7	Transcriptome-wide association analysis identified candidate susceptibility genes for nasopharyngeal carcinoma. <i>Cancer Communications</i> , 2022, 42, 887-891.	9.2	1
8	Associations between lncRNA-related polymorphisms and hepatocellular carcinoma risk: A two-stage case-control study. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 233-239.	2.8	2
9	Prospective assessment of a nasopharyngeal carcinoma risk score in a population undergoing screening. <i>International Journal of Cancer</i> , 2021, 148, 2398-2406.	5.1	9
10	Neoadjuvant chemotherapy followed by radical surgery versus concurrent chemoradiotherapy in patients with FIGO stage IIB cervical cancer: the CSEM 006 study. <i>International Journal of Gynecological Cancer</i> , 2021, 31, 129-133.	2.5	8
11	Comparison of the diagnostic performances of US-guided fine needle aspiration cytology and thyroglobulin measurement for lymph node metastases in patients with differentiated thyroid carcinoma: a meta-analysis. <i>European Radiology</i> , 2021, 31, 2903-2914.	4.5	11
12	Effectiveness of Sequential Chemoradiation vs Concurrent Chemoradiation or Radiation Alone in Adjuvant Treatment After Hysterectomy for Cervical Cancer. <i>JAMA Oncology</i> , 2021, 7, 361.	7.1	57
13	Droplet Cas12a Assay Enables DNA Quantification from Unamplified Samples at the Single-Molecule Level. <i>Nano Letters</i> , 2021, 21, 4643-4653.	9.1	120
14	Total Neoadjuvant Therapy (TNT) versus Standard Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer: A Systematic Review and Meta-Analysis. <i>Oncologist</i> , 2021, 26, e1555-e1566.	3.7	76
15	Residence characteristics and risk of nasopharyngeal carcinoma in southern China: A population-based case-control study. <i>Environment International</i> , 2021, 151, 106455.	10.0	11
16	lncRNA GAS8-AS1 genetic alterations in papillary thyroid carcinoma and their clinical significance. <i>Cancer Biomarkers</i> , 2020, 29, 255-264.	1.7	2
17	A 10-Year Study on Larynx Preservation Compared With Surgical Resection in Patients With Locally Advanced Laryngeal and Hypopharyngeal Cancers. <i>Frontiers in Oncology</i> , 2020, 10, 535893.	2.8	8
18	Efficacy and Safety of Locoregional Radiotherapy With Chemotherapy vs Chemotherapy Alone in De Novo Metastatic Nasopharyngeal Carcinoma. <i>JAMA Oncology</i> , 2020, 6, 1345.	7.1	137

#	ARTICLE	IF	CITATIONS
19	Polymorphisms in matricellular SPP1 and SPARC contribute to susceptibility to papillary thyroid cancer. <i>Genomics</i> , 2020, 112, 4959-4967.	2.9	6
20	CIK cell cytotoxicity is a predictive biomarker for CIK cell immunotherapy in postoperative patients with hepatocellular carcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 825-834.	4.2	14
21	A combination of two ELISA tests for nasopharyngeal carcinoma screening in endemic areas based on a case-control study. <i>PeerJ</i> , 2020, 8, e10254.	2.0	2
22	Is anatomical resection necessary for early hepatocellular carcinoma? A single institution retrospective experience. <i>Future Oncology</i> , 2019, 15, 2041-2051.	2.4	9
23	Polysaccharides from <i>Hedyotis diffusa</i> enhance the antitumor activities of cytokine-induced killer cells. <i>Biomedicine and Pharmacotherapy</i> , 2019, 117, 109167.	5.6	12
24	The prevalence of EML4-ALK variants in patients with non-small-cell lung cancer: a systematic review and meta-analysis. <i>Biomarkers in Medicine</i> , 2019, 13, 1035-1044.	1.4	18
25	Induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: long-term results of a phase III multicentre randomised controlled trial. <i>European Journal of Cancer</i> , 2019, 119, 87-96.	2.8	150
26	Smoking can increase nasopharyngeal carcinoma risk by repeatedly reactivating Epstein-Barr Virus: An analysis of a prospective study in southern China. <i>Cancer Medicine</i> , 2019, 8, 2561-2571.	2.8	19
27	Reproductive history and risk of nasopharyngeal carcinoma: A population-based case-control study in southern China. <i>Oral Oncology</i> , 2019, 88, 102-108.	1.5	8
28	Association Between Environmental Factors and Oral Epstein-Barr Virus DNA Loads: A Multicenter Cross-sectional Study in China. <i>Journal of Infectious Diseases</i> , 2019, 219, 400-409.	4.0	22
29	Dose-Dense Rituximab-CHOP versus Standard Rituximab-CHOP in Newly Diagnosed Chinese Patients with Diffuse Large B-Cell Lymphoma: A Randomized, Multicenter, Open-Label Phase 3 Trial. <i>Cancer Research and Treatment</i> , 2019, 51, 919-932.	3.0	14
30	The Relationship Between Environmental Factors and the Profile of Epstein-Barr Virus Antibodies in the Lytic and Latent Infection Periods in Healthy Populations from Endemic and Non-Endemic Nasopharyngeal Carcinoma Areas in China. <i>EBioMedicine</i> , 2018, 30, 184-191.	6.1	31
31	A Prognostic Bio-Model Based on SQSTM1 and N-Stage Identifies Nasopharyngeal Carcinoma Patients at High Risk of Metastasis for Additional Induction Chemotherapy. <i>Clinical Cancer Research</i> , 2018, 24, 648-658.	7.0	24
32	Thoracoscopic Surgery Versus Thoracotomy for Lung Cancer: Short-Term Outcomes of a Randomized Trial. <i>Annals of Thoracic Surgery</i> , 2018, 105, 386-392.	1.3	109
33	Apatinib combined with oral etoposide in patients with platinum-resistant or platinum-refractory ovarian cancer (AERO): a phase 2, single-arm, prospective study. <i>Lancet Oncology</i> , The, 2018, 19, 1239-1246.	10.7	130
34	Decreased macrophage inflammatory protein (MIP)-1 $\alpha$ and MIP-1 $\beta$ increase the risk of developing nasopharyngeal carcinoma. <i>Cancer Communications</i> , 2018, 38, 1-14.	9.2	14
35	Decreased oral Epstein-Barr virus DNA loads in patients with nasopharyngeal carcinoma in Southern China: A case-control and a family-based study. <i>Cancer Medicine</i> , 2018, 7, 3453-3464.	2.8	9
36	Establishment of an Adjusted Prognosis Analysis Model for Initially Diagnosed Non-Small-Cell Lung Cancer With Brain Metastases From Sun Yat-Sen University Cancer Center. <i>Clinical Lung Cancer</i> , 2017, 18, e179-e186.	2.6	4

#	ARTICLE	IF	CITATIONS
37	Noadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: A phase III multicentre randomised controlled trial. <i>European Journal of Cancer</i> , 2017, 75, 14-23.	2.8	226
38	Evaluation of seven recombinant VCA-IgA ELISA kits for the diagnosis of nasopharyngeal carcinoma in China: a case-control trial. <i>BMJ Open</i> , 2017, 7, e013211.	1.9	13
39	TNM Staging Matched-pair Comparison of Surgery After Neoadjuvant Chemoradiotherapy, Surgery Alone and Definitive Chemoradiotherapy for Thoracic Esophageal Squamous Cell Carcinoma. <i>Journal of Cancer</i> , 2017, 8, 683-690.	2.5	12
40	Clinicopathologic Characteristics and Prognosis of Tongue Squamous Cell Carcinoma in Patients with and without a History of Radiation for Nasopharyngeal Carcinoma: A Matched Case-Control Study. <i>Cancer Research and Treatment</i> , 2017, 49, 695-705.	3.0	15
41	The Attitudes of Chinese Cancer Patients and Family Caregivers toward Advance Directives. <i>International Journal of Environmental Research and Public Health</i> , 2016, 13, 816.	2.6	15
42	Subtype distribution and long-term titer fluctuation patterns of serum anti-Epstein-Barr virus antibodies in a non-nasopharyngeal carcinoma population from an endemic area in South China: a cohort study. <i>Chinese Journal of Cancer</i> , 2016, 35, 78.	4.9	10
43	Oral Hygiene and Risk of Nasopharyngeal Carcinoma: A Population-Based Case-Control Study in China. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2016, 25, 1201-1207.	2.5	46
44	Hydroxylated polybrominated diphenyl ethers (OH-PBDEs) in paired maternal and neonatal samples from South China: Placental transfer and potential risks. <i>Environmental Research</i> , 2016, 148, 72-78.	7.5	17
45	New risk factors and new tendency for central nervous system relapse in patients with diffuse large B-cell lymphoma: a retrospective study. <i>Chinese Journal of Cancer</i> , 2016, 35, 87.	4.9	15
46	Time trend analysis of primary liver cancer incidence in Sihui county of Guangdong Province, China (1987-2011). <i>BMC Cancer</i> , 2016, 16, 796.	2.6	7
47	Expression and prognostic role of ubiquitination factor E4B in primary hepatocellular carcinoma. <i>Molecular Carcinogenesis</i> , 2016, 55, 64-76.	2.7	24
48	Upregulation of PD-L1 by EML4-ALK fusion protein mediates the immune escape in ALK positive NSCLC: Implication for optional anti-PD-1/PD-L1 immune therapy for ALK-TKIs sensitive and resistant NSCLC patients. <i>Oncolmmunology</i> , 2016, 5, e1094598.	4.6	105
49	Risk stratification based on change in plasma Epstein-Barr virus DNA load after treatment in nasopharyngeal carcinoma. <i>Oncotarget</i> , 2016, 7, 9576-9585.	1.8	19
50	Estimation of cancer burden in Guangdong Province, China in 2009. <i>Chinese Journal of Cancer</i> , 2015, 34, 594-601.	4.9	13
51	Secular trend analysis of lung cancer incidence in Sihui city, China between 1987 and 2011. <i>Chinese Journal of Cancer</i> , 2015, 34, 365-72.	4.9	7
52	Incidence trend of nasopharyngeal carcinoma from 1987 to 2011 in Sihui County, Guangdong Province, South China: an age-period-cohort analysis. <i>Chinese Journal of Cancer</i> , 2015, 34, 350-7.	4.9	126
53	Salvage endoscopic nasopharyngectomy and intensity-modulated radiotherapy versus conventional radiotherapy in treating locally recurrent nasopharyngeal carcinoma. <i>Head and Neck</i> , 2015, 37, 1108-1115.	2.0	59
54	Hepatitis B Virus Infection and Risk of Nasopharyngeal Carcinoma in Southern China. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 1766-1773.	2.5	30

#	ARTICLE	IF	CITATIONS
55	A novel pathogenic germline mutation in the adenomatous polyposis coli gene in a Chinese family with familial adenomatous coli. <i>Oncotarget</i> , 2015, 6, 27267-27274.	1.8	9
56	A phase I clinical trial utilizing autologous tumor-infiltrating lymphocytes in patients with primary hepatocellular carcinoma. <i>Oncotarget</i> , 2015, 6, 41339-41349.	1.8	79
57	Serum apolipoprotein A-I is a novel prognostic indicator for non-metastatic nasopharyngeal carcinoma. <i>Oncotarget</i> , 2015, 6, 44037-44048.	1.8	25
58	Multicenter Randomized Phase 2 Clinical Trial of a Recombinant Human Endostatin Adenovirus in Patients with Advanced Head and Neck Carcinoma. <i>Molecular Therapy</i> , 2014, 22, 1221-1229.	8.2	36
59	Clinical Activity of Adjuvant Cytokine-Induced Killer Cell Immunotherapy in Patients with Post-Mastectomy Triple-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2014, 20, 3003-3011.	7.0	68
60	Familial nasopharyngeal carcinomas possess distinguished clinical characteristics in southern China. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2014, 26, 543-9.	2.2	11
61	Two Epstein-Barr Virus-Related Serologic Antibody Tests in Nasopharyngeal Carcinoma Screening: Results From the Initial Phase of a Cluster Randomized Controlled Trial in Southern China. <i>American Journal of Epidemiology</i> , 2013, 177, 242-250.	3.4	108
62	A Large Cohort Study Reveals the Association of Elevated Peripheral Blood Lymphocyte-to-Monocyte Ratio with Favorable Prognosis in Nasopharyngeal Carcinoma. <i>PLoS ONE</i> , 2013, 8, e83069.	2.5	115
63	Trends in the survival of patients with nasopharyngeal carcinoma between 1976 and 2005 in Sihui, China: a population-based study. <i>Chinese Journal of Cancer</i> , 2013, 32, 325-333.	4.9	28
64	Establishment of VCA and EBNA1 IgA-based combination by enzyme-linked immunosorbent assay as preferred screening method for nasopharyngeal carcinoma: a two-stage design with a preliminary performance study and a mass screening in southern China. <i>International Journal of Cancer</i> , 2012, 131, 406-416.	5.1	116
65	Fluctuations of Epstein-Barr Virus Serological Antibodies and Risk for Nasopharyngeal Carcinoma: A Prospective Screening Study with a 20-Year Follow-Up. <i>PLoS ONE</i> , 2011, 6, e19100.	2.5	129
66	Trends in incidence and mortality of nasopharyngeal carcinoma over a 20-year period (1978/1983-2002) in Sihui and Cangwu counties in southern China. <i>BMC Cancer</i> , 2006, 6, 178.	2.6	199